Scott McMeekin

Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article and Find Full Text PDF

March 2017

The pro-inflammatory effect of obesity on high grade serous ovarian cancer.

Authors:

Camille C Gunderson Kai Ding Justin Dvorak Kathleen N Moore D Scott McMeekin Doris M Benbrook

Gynecol Oncol 2016 10 15;143(1):40-45. Epub 2016 Jul 15.

Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma, 800 NE 10th Street, Oklahoma City, OK, USA. Electronic address:

View Article and Find Full Text PDF

October 2016

Quantitative measurement of adiposity using CT images to predict the benefit of bevacizumab-based chemotherapy in epithelial ovarian cancer patients.

Authors:

Yunzhi Wang Theresa Thai Kathleen Moore Kai Ding Scott McMeekin Hong Liu Bin Zheng

Oncol Lett 2016 Jul 31;12(1):680-686. Epub 2016 May 31.

School of Electrical and Computer Engineering, University of Oklahoma, Norman, OK 73019, USA.

View Article and Find Full Text PDF

July 2016

Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.

Authors:

D Scott McMeekin David L Tritchler David E Cohn David G Mutch Heather A Lankes Melissa A Geller Matthew A Powell Floor J Backes Lisa M Landrum Richard Zaino Russell D Broaddus Nilsa Ramirez Feng Gao Shamshad Ali Kathleen M Darcy Michael L Pearl Paul A DiSilvestro Shashikant B Lele Paul J Goodfellow

J Clin Oncol 2016 09 20;34(25):3062-8. Epub 2016 Jun 20.

D. Scott McMeekin and Lisa M. Landrum, University of Oklahoma Health Sciences Center, Oklahoma City, OK; David L. Tritchler, Heather A. Lankes, and Shamshad Ali, NRG Oncology Statistics and Data Management Center; Shashikant B. Lele, Roswell Park Cancer Institute, Buffalo; Michael L. Pearl, Stony Brook University Hospital, Stony Brook, NY; David E. Cohn, Floor J. Backes, and Paul J. Goodfellow, The Ohio State University; Nilsa Ramirez, Research Institute at Nationwide Children's Hospital, Columbus, OH; David G. Mutch, Matthew A. Powell, and Feng Gao, Washington University School of Medicine, St. Louis, MO; Melissa A. Geller, University of Minnesota, Minneapolis, MN; Richard Zaino, Penn State Milton S. Hersey Medical Center, Hershey, PA; Russell D. Broaddus, The University of Texas MD Anderson Cancer Center, Houston, TX; Kathleen M. Darcy, Women's Health Integrated Research Collective, Annandale, VA; and Paul A. DiSilvestro, Women and Infants Hospital of Rhode Island, Providence, RI.

View Article and Find Full Text PDF

September 2016

Exploitation of Exosomes as Nanocarriers for Gene-, Chemo-, and Immune-Therapy of Cancer.

Authors:

Akhil Srivastava Anish Babu Justyna Filant Katherine M Moxley Rachel Ruskin Danny Dhanasekaran Anil K Sood Scott McMeekin Rajagopal Ramesh

J Biomed Nanotechnol 2016 Jun;12(6):1159-73

View Article and Find Full Text PDF

June 2016

Primary and acquired platinum-resistance among women with high grade serous ovarian cancer.

Authors:

Katrina Slaughter Laura L Holman Eric L Thomas Camille C Gunderson Jacob K Lauer Kai Ding D Scott McMeekin Kathleen M Moore

Gynecol Oncol 2016 08 25;142(2):225-30. Epub 2016 May 25.

Section of Gynecologic Oncology, Stephenson Cancer Center at The University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.

View Article and Find Full Text PDF

August 2016

Initiation of a formalized precision medicine program in gynecologic oncology.

Authors:

Camille C Gunderson Michelle R Rowland Deborah L Wright Kelsi L Andrade Robert S Mannel D Scott McMeekin Kathleen N Moore

Gynecol Oncol 2016 Apr;141(1):24-8

Stephenson Cancer Center, University of Oklahoma Health Sciences Center, 800 NE 10th Street, Oklahoma City, OK 73104, USA. Electronic address:

View Article and Find Full Text PDF

April 2016

Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.

Authors:

Fanny Dao Brooke A Schlappe Jill Tseng Jenny Lester Alpa M Nick Susan K Lutgendorf Scott McMeekin Robert L Coleman Kathleen N Moore Beth Y Karlan Anil K Sood Douglas A Levine

Gynecol Oncol 2016 May 11;141(2):260-263. Epub 2016 Mar 11.

Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, NY, New York, United States. Electronic address:

View Article and Find Full Text PDF

May 2016

Early prediction of clinical benefit of treating ovarian cancer using quantitative CT image feature analysis.

Authors:

Yuchen Qiu Maxine Tan Scott McMeekin Theresa Thai Kai Ding Kathleen Moore Hong Liu Bin Zheng

Acta Radiol 2016 Sep 11;57(9):1149-55. Epub 2015 Dec 11.

School of Electrical and Computer Engineering, University of Oklahoma, Norman, Oklahoma, USA.

View Article and Find Full Text PDF

September 2016

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.

Authors:

W Marston Linehan Paul T Spellman Christopher J Ricketts Chad J Creighton Suzanne S Fei Caleb Davis David A Wheeler Bradley A Murray Laura Schmidt Cathy D Vocke Myron Peto Abu Amar M Al Mamun Eve Shinbrot Anurag Sethi Samira Brooks W Kimryn Rathmell Angela N Brooks Katherine A Hoadley A Gordon Robertson Denise Brooks Reanne Bowlby Sara Sadeghi Hui Shen Daniel J Weisenberger Moiz Bootwalla Stephen B Baylin Peter W Laird Andrew D Cherniack Gordon Saksena Scott Haake Jun Li Han Liang Yiling Lu Gordon B Mills Rehan Akbani Mark D M Leiserson Benjamin J Raphael Pavana Anur Donald Bottaro Laurence Albiges Nandita Barnabas Toni K Choueiri Bogdan Czerniak Andrew K Godwin A Ari Hakimi Thai H Ho James Hsieh Michael Ittmann William Y Kim Bhavani Krishnan Maria J Merino Kenna R Mills Shaw Victor E Reuter Ed Reznik Carl S Shelley Brian Shuch Sabina Signoretti Ramaprasad Srinivasan Pheroze Tamboli George Thomas Satish Tickoo Kenneth Burnett Daniel Crain Johanna Gardner Kevin Lau David Mallery Scott Morris Joseph D Paulauskis Robert J Penny Candace Shelton W Troy Shelton Mark Sherman Eric Thompson Peggy Yena Melissa T Avedon Jay Bowen Julie M Gastier-Foster Mark Gerken Kristen M Leraas Tara M Lichtenberg Nilsa C Ramirez Tracie Santos Lisa Wise Erik Zmuda John A Demchok Ina Felau Carolyn M Hutter Margi Sheth Heidi J Sofia Roy Tarnuzzer Zhining Wang Liming Yang Jean C Zenklusen Jiashan Zhang Brenda Ayala Julien Baboud Sudha Chudamani Jia Liu Laxmi Lolla Rashi Naresh Todd Pihl Qiang Sun Yunhu Wan Ye Wu Adrian Ally Miruna Balasundaram Saianand Balu Rameen Beroukhim Tom Bodenheimer Christian Buhay Yaron S N Butterfield Rebecca Carlsen Scott L Carter Hsu Chao Eric Chuah Amanda Clarke Kyle R Covington Mahmoud Dahdouli Ninad Dewal Noreen Dhalla Harsha V Doddapaneni Jennifer A Drummond Stacey B Gabriel Richard A Gibbs Ranabir Guin Walker Hale Alicia Hawes D Neil Hayes Robert A Holt Alan P Hoyle Stuart R Jefferys Steven J M Jones Corbin D Jones Divya Kalra Christie Kovar Lora Lewis Jie Li Yussanne Ma Marco A Marra Michael Mayo Shaowu Meng Matthew Meyerson Piotr A Mieczkowski Richard A Moore Donna Morton Lisle E Mose Andrew J Mungall Donna Muzny Joel S Parker Charles M Perou Jeffrey Roach Jacqueline E Schein Steven E Schumacher Yan Shi Janae V Simons Payal Sipahimalani Tara Skelly Matthew G Soloway Carrie Sougnez Angela Tam Donghui Tan Nina Thiessen Umadevi Veluvolu Min Wang Matthew D Wilkerson Tina Wong Junyuan Wu Liu Xi Jane Zhou Jason Bedford Fengju Chen Yao Fu Mark Gerstein David Haussler Katayoon Kasaian Phillip Lai Shiyun Ling Amie Radenbaugh David Van Den Berg John N Weinstein Jingchun Zhu Monique Albert Iakovina Alexopoulou Jeremiah J Andersen J Todd Auman John Bartlett Sheldon Bastacky Julie Bergsten Michael L Blute Lori Boice Roni J Bollag Jeff Boyd Erik Castle Ying-Bei Chen John C Cheville Erin Curley Benjamin Davies April DeVolk Rajiv Dhir Laura Dike John Eckman Jay Engel Jodi Harr Ronald Hrebinko Mei Huang Lori Huelsenbeck-Dill Mary Iacocca Bruce Jacobs Michael Lobis Jodi K Maranchie Scott McMeekin Jerome Myers Joel Nelson Jeremy Parfitt Anil Parwani Nicholas Petrelli Brenda Rabeno Somak Roy Andrew L Salner Joel Slaton Melissa Stanton R Houston Thompson Leigh Thorne Kelinda Tucker Paul M Weinberger Cynthia Winemiller Leigh Anne Zach Rosemary Zuna

N Engl J Med 2016 Jan 4;374(2):135-45. Epub 2015 Nov 4.

View Article and Find Full Text PDF

January 2016

Role of cystathionine beta synthase in lipid metabolism in ovarian cancer.

Authors:

Prabir K Chakraborty Xunhao Xiong Soumyajit Banerjee Mustafi Sounik Saha Danny Dhanasekaran Nawajes A Mandal Scott McMeekin Resham Bhattacharya Priyabrata Mukherjee

Oncotarget 2015 Nov;6(35):37367-84

Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.

View Article and Find Full Text PDF

November 2015

Associations between etiologic factors and mortality after endometrial cancer diagnosis: the NRG Oncology/Gynecologic Oncology Group 210 trial.

Authors:

Ashley S Felix D Scott McMeekin David Mutch Joan L Walker William T Creasman David E Cohn Shamshad Ali Richard G Moore Levi S Downs Olga B Ioffe Kay J Park Mark E Sherman Louise A Brinton

Gynecol Oncol 2015 Oct 1;139(1):70-6. Epub 2015 Sep 1.

Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article and Find Full Text PDF

October 2015

A New Approach to Evaluate Drug Treatment Response of Ovarian Cancer Patients Based on Deformable Image Registration.

Authors:

Maxine Tan Zheng Li Yuchen Qiu Scott D McMeekin Theresa C Thai Kai Ding Kathleen N Moore Hong Liu Bin Zheng

IEEE Trans Med Imaging 2016 Jan 27;35(1):316-25. Epub 2015 Aug 27.

View Article and Find Full Text PDF

January 2016

Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/ Gynecologic Oncology Group 210 Trial.

Authors:

Ashley S Felix Louise A Brinton D Scott McMeekin William T Creasman David Mutch David E Cohn Joan L Walker Richard G Moore Levi S Downs Robert A Soslow Richard Zaino Mark E Sherman

J Natl Cancer Inst 2015 Sep 18;107(9). Epub 2015 Jun 18.

: Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics (ASF, LAB) and Cancer Prevention Fellowship Program, Division of Cancer Prevention (ASF), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, OK (SM, JLW); Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC (WTC); Washington University School of Medicine, St. Louis, MO (DM); Division of Gynecologic Oncology, Ohio State University College of Medicine, Columbus, OH (DEC); Women and Infants Hospital/Brown University, Providence, RI (RGM); University of Minnesota, Minneapolis, MN (LSD); Memorial Sloan Kettering Cancer Center, New York, NY (RAS); Anatomic Pathology, Penn State Milton S. Hersey Medical Center, Hershey, PA (RZ); Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD (MES).

View Article and Find Full Text PDF

September 2015

A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study.

Authors:

D Scott McMeekin Michael W Sill Joan L Walker Kathleen N Moore Steven E Waggoner Premal H Thaker Tina Rizack James S Hoffman Paula M Fracasso

Gynecol Oncol 2015 Jul 6;138(1):36-40. Epub 2015 May 6.

University of Virginia, Charlottesville, VA, United States. Electronic address:

View Article and Find Full Text PDF

July 2015

Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer.

Authors:

Scott McMeekin Don Dizon James Barter Giovanni Scambia Lyudmila Manzyuk Alla Lisyanskaya Ana Oaknin Sarah Ringuette Pralay Mukhopadhyay Julie Rosenberg Ignace Vergote

Gynecol Oncol 2015 Jul 26;138(1):18-23. Epub 2015 Apr 26.

University Hospital Leuven, Leuven Cancer Institute, Department of Oncology, KU Leuven, Belgium.

View Article and Find Full Text PDF

July 2015

Role of TGF-β signaling in uterine carcinosarcoma.

Authors:

Shailendra Kumar Dhar Dwivedi Scott D McMeekin Katrina Slaughter Resham Bhattacharya

Oncotarget 2015 Jun;6(16):14646-55

Department of Obstetrics and Gynecology, Stephenson Cancer Center, University of Oklahoma Health Science Center, Oklahoma, USA.

View Article and Find Full Text PDF

June 2015

Exosomes: a role for naturally occurring nanovesicles in cancer growth, diagnosis and treatment.

Authors:

Akhil Srivastava Justyna Filant Katherine M Moxley Anil Sood Scott McMeekin Rajagopal Ramesh

Curr Gene Ther 2015 ;15(2):182-92

Department of Pathology, The Biomedical Research Center, Suite 1403, University of Oklahoma Health Sciences Center, 975 N.E., 10th Street, Oklahoma City, OK 73104, USA.

View Article and Find Full Text PDF

November 2015

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.

Authors:

Ursula Matulonis Ignace Vergote Floor Backes Lainie P Martin Scott McMeekin Michael Birrer Frank Campana Yi Xu Coumaran Egile Sharad Ghamande

Gynecol Oncol 2015 Feb 17;136(2):246-53. Epub 2014 Dec 17.

Georgia Regents University Cancer Center, Augusta, GA, USA.

View Article and Find Full Text PDF

February 2015

Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles.

Authors:

Xunhao Xiong Rochelle R Arvizo Sounik Saha David J Robertson Scott McMeekin Resham Bhattacharya Priyabrata Mukherjee

Oncotarget 2014 Aug;5(15):6453-65

Peggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.

View Article and Find Full Text PDF

August 2014

A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

Authors:

Matthew A Powell Michael W Sill Paul J Goodfellow Doris M Benbrook Heather A Lankes Kimberly K Leslie Yvette Jeske Robert S Mannel Monique A Spillman Paula S Lee James S Hoffman D Scott McMeekin Pamela M Pollock

Gynecol Oncol 2014 Oct 11;135(1):38-43. Epub 2014 Jul 11.

Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia. Electronic address:

View Article and Find Full Text PDF

October 2014

The survival detriment of venous thromboembolism with epithelial ovarian cancer.

Authors:

Camille C Gunderson Eric D Thomas Katrina N Slaughter Regina Farrell Kai Ding Ronni E Farris Jacob K Lauer LaToya J Perry D Scott McMeekin Kathleen N Moore

Gynecol Oncol 2014 Jul 1;134(1):73-7. Epub 2014 May 1.

University of Oklahoma Health Sciences Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Oklahoma City, OK, United States.

View Article and Find Full Text PDF

July 2014

Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.

Authors:

Katrina N Slaughter Theresa Thai Shayla Penaroza Doris M Benbrook Elangovan Thavathiru Kai Ding Tina Nelson D Scott McMeekin Kathleen N Moore

Gynecol Oncol 2014 Apr;133(1):11-5

University of Oklahoma Health Sciences Center, USA.

View Article and Find Full Text PDF

April 2014

Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors.

Authors:

Lisa M Landrum Elizabeth K Nugent Rosemary E Zuna Elizabeth Syzek Robert S Mannel Kathleen N Moore Joan L Walker D Scott McMeekin

Gynecol Oncol 2014 Jan 9;132(1):50-4. Epub 2013 Nov 9.

Section of Gynecology Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

View Article and Find Full Text PDF

January 2014

Referrals to phase I clinical trials in a gynecologic oncology unit.

Authors:

Katrina N Slaughter Elizabeth K Nugent Erin A Bishop Latoya J Perry D Scott McMeekin Kathleen N Moore

Gynecol Oncol 2014 Jan 14;132(1):231-5. Epub 2013 Sep 14.

University of Oklahoma Health Sciences Center, USA.

View Article and Find Full Text PDF

January 2014

Inpatient versus outpatient management of neutropenic fever in gynecologic oncology patients: is risk stratification useful?

Authors:

Camille C Gunderson Regina Farrell Brian C Dinh Eric D Thomas Sara K Vesely Jacob K Lauer Lydia Kao Sheeva Chopra D Scott McMeekin Kathleen N Moore

Gynecol Oncol 2013 Sep 20;130(3):411-5. Epub 2013 Jun 20.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Oklahoma Health Sciences Center, 800 NE 10th Street, Oklahoma City, OK 71304, USA.

View Article and Find Full Text PDF

September 2013

Phase II study of weekly PM00104 (ZALYPSIS(®)) in patients with pretreated advanced/metastatic endometrial or cervical cancer.

Authors:

Lainie P Martin Carolyn Krasner Teresa Rutledge Manuel Luque Ibañes Eva M Fernández-García Carmen Kahatt Mariano Siguero Gómez Scott McMeekin

Med Oncol 2013 15;30(3):627. Epub 2013 Jun 15.

Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.

View Article and Find Full Text PDF

April 2014

Distance traveled for treatment of cervical cancer: who travels the farthest, and does it impact outcome?

Authors:

Camille C Gunderson Elizabeth K Nugent D Scott McMeekin Kathleen N Moore

Int J Gynecol Cancer 2013 Jul;23(6):1099-103

Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

View Article and Find Full Text PDF

July 2013

Enhanced Fano resonance of organic material films deposited on arrays of asymmetric split-ring resonators (A-SRRs).

Authors:

Basudev Lahiri Scott G McMeekin Richard M De la Rue Nigel P Johnson

Opt Express 2013 Apr;21(8):9343-52

School of Engineering, University of Glasgow, Glasgow G12 8LT, UK.

View Article and Find Full Text PDF

April 2013

A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors.

Authors:

Shubham Pant Howard A Burris Kathleen Moore Johanna C Bendell Carla Kurkjian Suzanne F Jones Ofir Moreno John G Kuhn Scott McMeekin Jeffrey R Infante

Invest New Drugs 2014 Feb 24;32(1):87-93. Epub 2013 Mar 24.

SCRI, University of Oklahoma, Oklahoma City, OK, USA.

View Article and Find Full Text PDF

February 2014

Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.

Authors:

Louise A Brinton Ashley S Felix D Scott McMeekin William T Creasman Mark E Sherman David Mutch David E Cohn Joan L Walker Richard G Moore Levi S Downs Robert A Soslow Richard Zaino

Gynecol Oncol 2013 May 26;129(2):277-84. Epub 2013 Feb 26.

Hormonal and Reproductive Epidemiology Branch, National Cancer Institute, Rockville, MD 20852, USA.

View Article and Find Full Text PDF

May 2013

Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials.

Authors:

José María del Campo Cristiana Sessa Carolyn N Krasner Jan B Vermorken Nicoletta Colombo Stan Kaye Martin Gore Patrik Zintl Javier Gómez Trilok Parekh Youn Choi Park Scott McMeekin

Med Oncol 2013 Mar 9;30(1):435. Epub 2013 Feb 9.

Gynecological, Head and Neck Cancer Division, Department of Medical Oncology, Vall d'Hebron University Hospital, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.

View Article and Find Full Text PDF

March 2013

A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.

Authors:

Robert L Coleman Michael W Sill Heather A Lankes Amanda Nickles Fader Neil J Finkler James S Hoffman Peter G Rose Gregory P Sutton Charles W Drescher D Scott McMeekin Wei Hu Michael Deavers Andrew K Godwin R Katherine Alpaugh Anil K Sood

Gynecol Oncol 2012 Dec 23;127(3):538-43. Epub 2012 Aug 23.

Dept. of Gynecologic Oncology & Reproductive Medicine, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article and Find Full Text PDF

December 2012

A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study.

Authors:

D Scott McMeekin Michael W Sill Kathleen M Darcy Ovadia Abulafia Parviz Hanjani Michael L Pearl Stephen C Rubin Peter G Rose Laurie Small Doris Mangiaracina Benbrook

Gynecol Oncol 2012 Nov 14;127(2):356-61. Epub 2012 Jul 14.

Department of Obstetrics and Gynecology, Gynecologic Oncology Section, University of Oklahoma, Oklahoma City, OK 73104, USA.

View Article and Find Full Text PDF

November 2012

Designing the next lymphadenectomy trial: what should we learn for our prior experiences.

Authors:

D Scott McMeekin

Gynecol Oncol 2012 Jul;126(1):1-2

View Article and Find Full Text PDF

July 2012

A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study.

Authors:

Peter G Rose Michael W Sill D Scott McMeekin Amina Ahmed Ritu Salani S Diane Yamada Aaron H Wolfson Nancy Fusco Paula M Fracasso

Gynecol Oncol 2012 Apr 22;125(1):158-62. Epub 2011 Dec 22.

Case Western Reserve University, Cleveland, OH 44195, USA.

View Article and Find Full Text PDF

April 2012

Serum profiling to distinguish early- and late-stage ovarian cancer patients from disease-free individuals.

Authors:

James R Hocker Erin A Bishop Stan A Lightfoot Megan R Lerner Marvin D Peyton Daniel J Brackett Rushie J Hanas D Scott McMeekin Joan L Walker Jay S Hanas

Cancer Invest 2012 Feb 7;30(2):189-97. Epub 2011 Dec 7.

Department of Biochemistry & Molecular Biology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma 73104, USA.

View Article and Find Full Text PDF

February 2012

What should lymphadenectomy offer in early-stage endometrial cancer: lots of variables, little control.

Authors:

D Scott McMeekin

Am J Obstet Gynecol 2011 Dec 16;205(6):509-10. Epub 2011 Sep 16.

View Article and Find Full Text PDF

December 2011

Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.

Authors:

Alan N Gordon Michael Teneriello Mike F Janicek Jeffrey Hines Peter C Lim M Dwight Chen Luis Vaccarello Howard D Homesley Scott McMeekin Tiana L Burkholder Yanping Wang Luping Zhao Mauro Orlando Coleman K Obasaju John F Gill Datchen F Tai

Gynecol Oncol 2011 Dec 5;123(3):479-85. Epub 2011 Oct 5.

M.D. Anderson Cancer Center Orlando, 1400 S. Orange Avenue, Orlando, FL 32806, USA.

View Article and Find Full Text PDF

December 2011

Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.

Authors:

Alessandro D Santin Michael W Sill D Scott McMeekin Mario M Leitao Jubilee Brown Gregory P Sutton Linda Van Le Patricia Griffin Cecelia H Boardman

Gynecol Oncol 2011 Sep;122(3):495-500

Yale University School of Medicine, Department of Obstetrics, Gynecology & Reproductive Sciences, New Haven, CT 06520-8063, USA.

View Article and Find Full Text PDF

September 2011

Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer.

Authors:

Lisa M Landrum Johnny Hyde Robert S Mannel D Scott McMeekin Kathleen N Moore Joan L Walker

Gynecol Oncol 2011 Sep 12;122(3):527-31. Epub 2011 Jun 12.

University of Oklahoma Health Sciences Center, Section of Gynecology Oncology, Oklahoma City, OK 73190, USA.

View Article and Find Full Text PDF

September 2011

Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.

Authors:

Carol Aghajanian Michael W Sill Kathleen M Darcy Benjamin Greer D Scott McMeekin Peter G Rose Jacob Rotmensch Mack N Barnes Parviz Hanjani Kimberly K Leslie

J Clin Oncol 2011 Jun 2;29(16):2259-65. Epub 2011 May 2.

Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article and Find Full Text PDF

June 2011

A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study.

Authors:

Robert L Coleman William E Brady D Scott McMeekin Peter G Rose John T Soper Samuel S Lentz James S Hoffman Mark S Shahin

Gynecol Oncol 2011 Jul 15;122(1):111-5. Epub 2011 Apr 15.

Department of Gynecologic Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article and Find Full Text PDF

July 2011

A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial.

Authors:

Russell J Schilder John A Blessing Mark S Shahin David S Miller Krishnansu Sujata Tewari Carolyn Y Muller David P Warshal Scott McMeekin Jacob Rotmensch

Int J Gynecol Cancer 2010 Oct;20(7):1137-41

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

View Article and Find Full Text PDF

October 2010

Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review.

Authors:

Robert W Holloway Edward C Grendys Patrick Lefebvre Francis Vekeman Scott McMeekin

Oncologist 2010 7;15(10):1073-82. Epub 2010 Oct 7.

Florida Hospital Cancer Institute, Orlando, Florida 32804, USA.

View Article and Find Full Text PDF

February 2011

Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents.

Authors:

Katherine M Moxley D Scott McMeekin

Oncologist 2010 7;15(10):1026-33. Epub 2010 Oct 7.

University of Oklahoma Health Sciences Center, 4502 East 41st Street, Tulsa, Oklahoma 74135, USA.

View Article and Find Full Text PDF

February 2011

Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study.

Authors:

David Cella Helen Q Huang Bradley J Monk Lari Wenzel Jo Benda D Scott McMeekin David Cohn Lois Ramondetta Cecelia H Boardman

Gynecol Oncol 2010 Dec 15;119(3):531-7. Epub 2010 Sep 15.

Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.

View Article and Find Full Text PDF

December 2010

Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis.

Authors:

Kathleen N Moore Chunqiao Tian D Scott McMeekin J Tate Thigpen Marcus E Randall Holly H Gallion

Cancer 2010 Dec 24;116(23):5407-14. Epub 2010 Aug 24.

Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, Oklahoma 73104, USA.

View Article and Find Full Text PDF

December 2010

Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma.

Authors:

Vladislav Zakharov Hsueh-Kung Lin Joseph Azzarello Scott McMeekin Kathleen N Moore Trevor M Penning Kar-Ming Fung

Int J Clin Exp Pathol 2010 Jul 5;3(6):608-17. Epub 2010 Jul 5.

Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

View Article and Find Full Text PDF

July 2010

A GOG 210 aCGH study of gain at 1q23 in endometrioid endometrial cancer in the context of racial disparity and outcome.

Authors:

Carl Morrison Jeffrey Miecznikowski Kathleen M Darcy Jean M Dolce Eugene Kandel Deborah O Erwin Song Liu Lori Shepherd David Cohn D Scott McMeekin Annemarie W Block Norma J Nowak Larry Maxwell

Genes Chromosomes Cancer 2010 Sep;49(9):791-802

Division of Molecular Pathology, Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

View Article and Find Full Text PDF

September 2010

Necessity of radical hysterectomy for endometrial cancer patients with cervical invasion.

Authors:

Taek Sang Lee Jae Weon Kim Dae Yeon Kim Young Tae Kim Ki Heon Lee Byoung Gie Kim D Scott McMeekin

J Korean Med Sci 2010 Apr 19;25(4):552-6. Epub 2010 Mar 19.

Department of Obstetrics and Gynecology, Seoul Metropolitan Boramae Hospital, Seoul, Korea.

View Article and Find Full Text PDF

April 2010

Magnetic response of split ring resonators (SRRs) at visible frequencies.

Authors:

Basudev Lahiri Scott G McMeekin Ali Z Khokhar Richard M De La Rue Nigel P Johnson

Opt Express 2010 Feb;18(3):3210-8

Department of Electronics and Electrical Engineering, University of Glasgow, Glasgow G12 8LT, UK.

View Article and Find Full Text PDF

February 2010

Ultra-early predictive assay for treatment failure using functional magnetic resonance imaging and clinical prognostic parameters in cervical cancer.

Authors:

Nina A Mayr William T C Yuh David Jajoura Jian Z Wang Simon S Lo Joseph F Montebello Kyle Porter Dongqing Zhang D Scott McMeekin John M Buatti

Cancer 2010 Feb;116(4):903-12

Department of Radiation Oncology, College for Public Health, Ohio State University, Columbus, OH 43210, USA.

View Article and Find Full Text PDF

February 2010

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.

Authors:

Gini F Fleming Michael W Sill Kathleen M Darcy D Scott McMeekin J Tate Thigpen Lisa M Adler Jonathan S Berek Julia A Chapman Paul A DiSilvestro Ira R Horowitz James V Fiorica

Gynecol Oncol 2010 Jan 18;116(1):15-20. Epub 2009 Oct 18.

University of Chicago Medical Center, 5841 South Maryland Avenue, MC 2115, Chicago, IL 60637, USA.

View Article and Find Full Text PDF

January 2010

A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology.

Authors:

David Scott Miller John A Blessing Richard D Drake Robert Higgins D Scott McMeekin Louis V Puneky Carolyn N Krasner

Gynecol Oncol 2009 Dec 4;115(3):443-6. Epub 2009 Oct 4.

Division of Gynecologic Oncology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Room J7-124, Dallas, TX 75390-9032, USA.

View Article and Find Full Text PDF

December 2009

Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.

Authors:

Bradley J Monk Michael W Sill D Scott McMeekin David E Cohn Lois M Ramondetta Cecelia H Boardman Jo Benda David Cella

J Clin Oncol 2009 Oct 31;27(28):4649-55. Epub 2009 Aug 31.

University of California, Irvine Medical Center, Orange, CA 92868, USA.

View Article and Find Full Text PDF

October 2009

Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P.

Authors:

Don S Dizon John A Blessing D Scott McMeekin Sudarshan K Sharma Paul Disilvestro Ronald D Alvarez

J Clin Oncol 2009 Jul 18;27(19):3104-8. Epub 2009 May 18.

Program in Women's Oncology of Women and Infants, Hospital/Warren Alpert Medical School of Brown University, 101 Dudley St, Providence, RI 92905, USA.

View Article and Find Full Text PDF

July 2009

Vulvar cancer in young women: demographic features and outcome evaluation.

Authors:

Grainger S Lanneau Peter A Argenta Marion S Lanneau Robert H Riffenburgh Michael A Gold D Scott McMeekin Nancy Webster Patricia L Judson

Am J Obstet Gynecol 2009 Jun 16;200(6):645.e1-5. Epub 2009 Mar 16.

Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

View Article and Find Full Text PDF

June 2009

Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population?

Authors:

Kathleen N Moore Summer G Frank Erin K Alward Lisa M Landrum Tashanna K Myers Joan L Walker Michael A Gold D Scott McMeekin Sara K Vesely Robert S Mannel

Cancer 2009 Apr;115(7):1472-80

Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, Oklahoma 73104, USA.

View Article and Find Full Text PDF

April 2009

Asymmetric split ring resonators for optical sensing of organic materials.

Authors:

Basudev Lahiri Ali Z Khokhar Richard M De La Rue Scott G McMeekin Nigel P Johnson

Opt Express 2009 Jan;17(2):1107-15

Department of Electronics and Electrical Engineering, University of Glasgow, Glasgow, G12 8LT, UK.

View Article and Find Full Text PDF

January 2009

Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.

Authors:

Lisa M Landrum Kathleen N Moore Tashanna K N Myers Grainger S Lanneau D Scott McMeekin Joan L Walker Michael A Gold

Gynecol Oncol 2009 Feb 28;112(2):337-41. Epub 2008 Nov 28.

Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

View Article and Find Full Text PDF

February 2009

Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study.

Authors:

D Scott McMeekin Joan L Walker Ellen M Hartenbach Michael A Bookman Wui-Jin Koh

Gynecol Oncol 2009 Jan 29;112(1):134-41. Epub 2008 Oct 29.

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, OK 73190, USA.

View Article and Find Full Text PDF

January 2009

A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.

Authors:

Richard G Moore D Scott McMeekin Amy K Brown Paul DiSilvestro M Craig Miller W Jeffrey Allard Walter Gajewski Robert Kurman Robert C Bast Steven J Skates

Gynecol Oncol 2009 Jan 12;112(1):40-6. Epub 2008 Oct 12.

Program in Women's Oncology, Women and Infants' Hospital, Brown University, Providence, RI 02925, USA.

View Article and Find Full Text PDF

January 2009

Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?

Authors:

Kathleen N Moore Monica S Reid Daniel N Fong Tashanna K N Myers Lisa M Landrum Katherine M Moxley Joan L Walker D Scott McMeekin Robert S Mannel

Gynecol Oncol 2008 Aug 20;110(2):133-9. Epub 2008 May 20.

University of Oklahoma Health Sciences Center, Division of Gynecologic Oncology, Oklahoma City, Oklahoma 73103, USA.

View Article and Find Full Text PDF

August 2008

Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomes.

Authors:

Kathleen N Moore Michael A Gold D Scott McMeekin Joan L Walker Teresa Rutledge Kristin K Zorn

Gynecol Oncol 2008 Mar 14;108(3):466-71. Epub 2008 Jan 14.

University of Oklahoma, Division of Gynecologic Oncology, 920 SL Young Boulevard, Oklahoma City, OK, USA.

View Article and Find Full Text PDF

March 2008

Comparison of outcome measures in patients with advanced squamous cell carcinoma of the vulva treated with surgery or primary chemoradiation.

Authors:

Lisa M Landrum Valerie Skaggs Natalie Gould Joan L Walker D Scott McMeekin

Gynecol Oncol 2008 Mar 26;108(3):584-90. Epub 2007 Dec 26.

Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Oklahoma Health Sciences Center, PO Box 26901, Williams Pavilion 2410, Oklahoma City, OK 73190, USA.

View Article and Find Full Text PDF

March 2008

A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study.

Authors:

Peter G Rose Koen Degeest Scott McMeekin Nancy Fusco

Gynecol Oncol 2007 Nov 3;107(2):274-9. Epub 2007 Aug 3.

Case Western Reserve University and Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

View Article and Find Full Text PDF

November 2007

A phase II study of weekly docetaxel for patients with advanced or recurrent cancer of the cervix.

Authors:

Michael L Pearl Carolyn M Johnston D Scott McMeekin

Gynecol Obstet Invest 2007 30;64(4):193-8. Epub 2007 Jul 30.

Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Medicine, State University of New York at Stony Brook, Stony Brook, NY, USA.

View Article and Find Full Text PDF

December 2007

Pathologic findings and outcomes for octogenarians presenting with uterine malignancy.

Authors:

Kathleen N Moore Grainger S Lanneau Chad Smith Marion Lanneau Joan L Walker Michael A Gold D Scott McMeekin

Gynecol Oncol 2007 Sep 5;106(3):572-8. Epub 2007 Jul 5.

University of Oklahoma Division of Gynecologic Oncology, 920 SL Young Blvd., Oklahoma City, OK 73103, USA.

View Article and Find Full Text PDF

September 2007

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

Authors:

David G Mutch Mauro Orlando Tiana Goss Michael G Teneriello Alan N Gordon Scott D McMeekin Yanping Wang Dennis R Scribner Martin Marciniack R Wendel Naumann Angeles Alvarez Secord

J Clin Oncol 2007 Jul;25(19):2811-8

Washington University School of Medicine, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, St. Louis, MO 63110, USA.

View Article and Find Full Text PDF

July 2007

A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.

Authors:

D Scott McMeekin Michael W Sill Kathleen M Darcy Deborah J Stearns-Kurosawa Kenneth Webster Steven Waggoner Doris Benbrook

Gynecol Oncol 2007 Sep 27;106(3):596-603. Epub 2007 Jun 27.

University of Oklahoma, Department of Gynecologic Oncology, Health Sciences Center, OB/GYN, Oklahoma City, OK 73190, and Department of Reproductive Medicine, University Hospitals of Cleveland, OH 44106, USA.

View Article and Find Full Text PDF

September 2007

The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.

Authors:

D Scott McMeekin Virginia L Filiaci J Tate Thigpen Holly H Gallion Gini F Fleming William H Rodgers

Gynecol Oncol 2007 Jul;106(1):16-22

Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, OK 73190, USA.

View Article and Find Full Text PDF

July 2007

Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma.

Authors:

Kathleen N Moore Michael A Gold D Scott McMeekin Kristin K Zorn

Gynecol Oncol 2007 Sep 11;106(3):498-501. Epub 2007 Jun 11.

University of Oklahoma Health Sciences Center, 920 SL Young Blvd, WP 2470, Oklahoma City, OK, USA.

View Article and Find Full Text PDF

September 2007

Gynecologic Oncology Group risk groups for vulvar carcinoma: improvement in survival in the modern era.

Authors:

Lisa M Landrum Grainger S Lanneau Valerie J Skaggs Natalie Gould Joan L Walker D Scott McMeekin Michael A Gold

Gynecol Oncol 2007 Sep 31;106(3):521-5. Epub 2007 May 31.

Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, Oklahoma University Health Sciences Center, PO Box 26901, WP2410, Oklahoma City, OK 73190, USA.

View Article and Find Full Text PDF

September 2007

Clinical and pathologic correlates in surgical stage II endometrial carcinoma.

Authors:

David E Cohn Emily M Woeste Stacey Cacchio Vanna L Zanagnolo Laura J Havrilesky Andrea Mariani Karl C Podratz Warner K Huh Jenny M Whitworth D Scott McMeekin Matthew A Powell Emily Boyd Gary S Phillips Jeffrey M Fowler

Obstet Gynecol 2007 May;109(5):1062-7

Division of Gynecologic Oncology, Ohio State University College of Medicine, Columbus, Ohio, USA.

View Article and Find Full Text PDF

May 2007

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

Authors:

D Scott McMeekin Michael W Sill Doris Benbrook Kathleen M Darcy Deborah J Stearns-Kurosawa Lynne Eaton S Diane Yamada

Gynecol Oncol 2007 May 15;105(2):508-16. Epub 2007 Feb 15.

Department of Gynecologic Oncology, Health Sciences Center, OB/GYN, P.O. Box 26901, Williams Pavilion-Room WP2470, Oklahoma City, OK 73190, USA.

View Article and Find Full Text PDF

May 2007

Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group.

Authors:

Michael A Bookman D Scott McMeekin Paula M Fracasso

Gynecol Oncol 2006 Nov 2;103(2):473-8. Epub 2006 May 2.

Division of Medical Science, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

View Article and Find Full Text PDF

November 2006

Consolidation therapy in ovarian cancer: where do we stand?

Authors:

Daynelle D Dearnley D Scott McMeekin

Curr Opin Obstet Gynecol 2006 Feb;18(1):3-7

University of Oklahoma, Division of Gynecologic Oncology, Oklahoma City, Oklahoma 73104, USA.

View Article and Find Full Text PDF

February 2006

Preoperative predictors of positive margins after loop electrosurgical excisional procedure-Cone.

Authors:

Todd D Tillmanns Camille A Falkner David B Engle Jim Y Wan Robert S Mannel Joan L Walker Gary A Johnson D Scott McMeekin Rosemarry Zuna Michael A Gold

Gynecol Oncol 2006 Feb;100(2):379-84

Department of Obstetrics and Gynecology, University of Tennessee at Memphis, 854 Jefferson Ave., Room E-102, Memphis, TN 38163, USA.

View Article and Find Full Text PDF

February 2006

Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.

Authors:

Cheryl A Brewer John A Blessing Robert A Nagourney D Scott McMeekin Shashikant Lele Susan L Zweizig

Gynecol Oncol 2006 Feb 4;100(2):385-8. Epub 2005 Nov 4.

Division of Gynecologic Oncology, University of California Irvine Medical Center, Orange, CA 92868, USA.

View Article and Find Full Text PDF

February 2006

Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study.

Authors:

Harry J Long Bradley J Monk Helen Q Huang Edward C Grendys D Scott McMeekin Joel Sorosky David S Miller Lynne A Eaton James V Fiorica

Gynecol Oncol 2006 Mar 10;100(3):537-43. Epub 2005 Oct 10.

Mayo Clinic, Department of Medical Oncology, East 12B Mayo Building, 200 First Street, Southwest, Rochester, MN 55905-0001, USA.

View Article and Find Full Text PDF

March 2006

Carcinosarcoma of the ovary-a case series.

Authors:

Teresa L Rutledge Michael A Gold D Scott McMeekin Warner K Huh Matthew A Powell Sharyn N Lewin David G Mutch Gary A Johnson Joan L Walker Robert S Mannel

Gynecol Oncol 2006 Jan 5;100(1):128-32. Epub 2005 Oct 5.

University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

View Article and Find Full Text PDF

January 2006

Patients with malignancy requiring urgent therapy: CASE 3. Tumor lysis syndrome associated with chemotherapy in ovarian cancer.

Authors:

John K Chan Susan S Lin D Scott McMeekin Michael L Berman

J Clin Oncol 2005 Sep;23(27):6794-5

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA, USA.

View Article and Find Full Text PDF

September 2005

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.

Authors:

Harry J Long Brian N Bundy Edward C Grendys Jo Ann Benda D Scott McMeekin Joel Sorosky David S Miller Lynne A Eaton James V Fiorica

J Clin Oncol 2005 Jul 23;23(21):4626-33. Epub 2005 May 23.

Mayo Clinic College of Medicine, Rochester, MN, USA.

View Article and Find Full Text PDF

July 2005

Targeted therapies for gynecologic malignancies.

Authors:

Johnny Hyde D Scott McMeekin

Curr Treat Options Oncol 2005 Mar;6(2):121-32

University of Oklahoma- HSC, PO Box 26901, Oklahoma City, OK 73190, USA.

View Article and Find Full Text PDF

March 2005

Role of pegylated liposomal doxorubicin in ovarian cancer.

Authors:

J Tate Thigpen Carol A Aghajanian David S Alberts Susana M Campos Alan N Gordon Maurie Markman D Scott McMeekin Bradley J Monk Peter G Rose

Gynecol Oncol 2005 Jan;96(1):10-8

Division of Oncology, Department of Medicine, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA.

View Article and Find Full Text PDF

January 2005

Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer.

Authors:

D Scott McMeekin Todd Tillmanns Taimur Chaudry Michael Gold Gary Johnson Joan Walker Robert Mannel

Gynecol Oncol 2004 Oct;95(1):157-64

Division Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73109, USA.

View Article and Find Full Text PDF

October 2004

A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?

Authors:

Teresa L Rutledge Scott A Kamelle Todd D Tillmanns Natalie S Gould Jason D Wright David E Cohn Thomas J Herzog Janet S Rader Michael A Gold Gary A Johnson Joan L Walker Robert S Mannel D Scott McMeekin

Gynecol Oncol 2004 Oct;95(1):70-6

University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

View Article and Find Full Text PDF

October 2004

Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply?

Authors:

Scott A Kamelle Teresa L Rutledge Todd D Tillmanns Natalie S Gould David E Cohn Jason Wright Thomas J Herzog Janet S Rader Michael A Gold Gary A Johnson Joan L Walker Robert S Mannel D Scott McMeekin

Gynecol Oncol 2004 Aug;94(2):249-55

Oklahoma Health Sciences Center, USA.

View Article and Find Full Text PDF

August 2004

Laparoscopic management of cervical cancer: because we can, or because we should?

Authors:

D Scott McMeekin

Gynecol Oncol 2004 Jun;93(3):586-7

View Article and Find Full Text PDF

June 2004

A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.

Cancer 2004 Feb;100(4):859-68

Division of Hematology and Medical Oncology, Caritas St. Elizabeth's Medical Center, Boston, Massachusetts 02135, USA.

View Article and Find Full Text PDF

February 2004

Matched unrelated donor bone marrow transplantation for the treatment of platinum refractory ovarian carcinoma: a case report.

Authors:

Michele L Donato Charles Levenback David M Gershenson Scott McMeekin Richard E Champlin

Gynecol Oncol 2004 Jan;92(1):365-7

Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4095, USA.

View Article and Find Full Text PDF

January 2004

Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study.

Authors:

David Scott Miller John A Blessing Samuel S Lentz D Scott McMeekin

Cancer 2003 Oct;98(8):1664-9

Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

View Article and Find Full Text PDF

October 2003

A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer.

Authors:

D Scott McMeekin Alan Gordon Jeffrey Fowler Allen Melemed Richard Buller Thomas Burke Jeffery Bloss Paul Sabbatini

Gynecol Oncol 2003 Jul;90(1):64-9

University of Oklahoma, Oklahoma City, OK 73190, USA.

View Article and Find Full Text PDF

July 2003

Impact of individual physicians on enrollment of patients into clinical trials.

Authors:

Robert S Mannel Joan L Walker Natalie Gould Dennis R Scribner Scott Kamelle Todd Tillmanns D Scott McMeekin Michael A Gold

Am J Clin Oncol 2003 Apr;26(2):171-3

Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, U.S.A.

View Article and Find Full Text PDF

April 2003

Endometrial cancer: treatment of nodal metastases.

Authors:

D Scott McMeekin Todd Tillmanns

Curr Treat Options Oncol 2003 Apr;4(2):121-30

University of Oklahoma, Health Science Center, PO Box 26901, Oklahoma City, OK 73190, USA.

View Article and Find Full Text PDF

April 2003

Publications by authors named "Scott McMeekin"

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors:

Authors: